At ARVO 2026, EssilorLuxottica presented new research highlighting long-term outcomes with Essilor Stellest lenses, including seven-year follow-up data showing sustained efficacy in children and adolescents.
Results from the seven-year follow up in China by Li X et al showed that Essilor Stellest lenses (highly aspherical lenslet (HAL) spectacle lenses) reduced myopia progression by 2.30D and axial elongation by 0.92mm on average compared with single-vision lenses. The outcomes observed in adolescents up to 19 years of age also showed a reduced risk of developing high myopia. This study is among the longest reported evaluations of a spectacle lens myopia-control intervention and provides insight into outcomes through late adolescence, said EssilorLuxottica.
Further evidence presented came from a prospective, randomised, multicentre clinical trial in the US involving children aged six to 12 years. Conducted by Shen J et al, the study found Essilor Stellest lenses slowed myopia progression by 71% on average and reduced axial elongation by 53% over two years compared with single-vision lenses. The study also reported stable visual acuity and high compliance and retention rates throughout the trial period.
Effective across diverse patient populations
EssilorLuxottica also highlighted a review of published evidence spanning 26 studies conducted across multiple patient populations. According to an ARVO poster presented by Bullimore M et al, children wearing HAL spectacle lenses consistently demonstrated lower axial elongation than those wearing single-vision lenses, regardless of study design or geographic location.
